All News

DM.sine_.jpg

Dazukibart Effective in Adults with Dermatomyositis

Jack Cush, MD

Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).

Read Article
RheumNow Podcast square

Bah Humbug Vitamin D (12.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
question-mark-1872634_640.jpg

ICYMI: JAKi in inflammatory myositis?

Janet Pope, MD, MPH, FRCPC

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
RheumNow Podcast square

Don’t Buy Guitars (12.6.2024)

Jack Cush, MD

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
question-mark-1872634_640.jpg

JAKi in inflammatory myositis?

Janet Pope, MD, MPH, FRCPC

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
Meeting audience conference

ACR 2024 - Day 1 Report

Jack Cush, MD

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.

Read Article
Nipocalimab, a mAb that blocks FcRn, was granted a Priority Review from the FDA. J&J has submitted Biologics License Application (BLA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) myasthenia gravis based on Phase 3 Vivacity-MG3 study.… https://t.co/6sVbrgTBvF https://t.co/9a1dBWz87R
Dr. John Cush RheumNow ( View Tweet)
Retrospectively review of 165 #EGPA pts, GI manifestations were assoc w/ Eosinophils > 19.5%, weight loss, & myalgia; & included abdominal pain (78%), diarrhea (40%), N/V (33%); GI hemorrhage (27%), ulcers (17%), obstruction (10%), & pancreatitis (6%) https://t.co/EzsGcFs2l2 https://t.co/mQrgjTG6NV

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis… https://t.co/8XOYOsDsD4 https://t.co/MF0EGO0BJz
Dr. John Cush RheumNow ( View Tweet)
Nailfold video-capillaroscopy (NVC) study of 76 dermatomyositis (DM) pts - 74% had anomalous NVC patterns (diminished density, abnl morphology). NVC abnl pts had more Raynaud's, and cluster 1 were more likely to develop ILD.https://t.co/OC7jNHdFMn https://t.co/cCCO70Xzoh

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR24 take homes ➡️#Inflammatory #myositis #Upadacitinib improved MDA5 ILD #Baricitinib 4mg/d good in myositis delayed start #RCT #Tofacitinb ➡️help for skin, calcinosis, rash in case series ➡️RCT ongoing JAKi is ‘jacked’ in muscles 💪🏿 #ACR24 @RheumNow @ACRheum 1731 0348

Janet Pope Janetbirdope ( View Tweet)

The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD It consists of a combination of giant capillaries, some microhemorrhages, severe capillary loss and angiogenesis @RheumNow #ACR24 @rheumarhyme https://t.co/WO9BOYn4ir

Links:

sheila RHEUMarampa ( View Tweet)
#MDA5 #dermatomyositis assoc #ILD May do better w #tofacitinib vs #CNI in 515 pts Too bad they didn’t do a pragmatic RCT as we do t know the reasons for prescribing each #Rx But impressive survival w #tofa #ACR24 @ACRheum @RheumNow abst1736 https://t.co/HLJknSYcNJ

Links:

Janet Pope Janetbirdope ( View Tweet)
The 🫀is muscle‼️ 💥From the maestro herself @JuliePaikMD underscores why cardiac involvement in myositis can't be overlooked. 🔥Crucial insights with major implications for patient care and outcomes #acr24 @RheumNow @HopkinsMedicine @jhrheumatology https://t.co/mw6BvkdF2w

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec

Links:

Richard Conway RichardPAConway ( View Tweet)
#1156 @DidemSayginMD et al finds that ~1/3 patients with myositis have comorbid fibromyalgia ➡️Presence of fibromyalgia significantly impacted patient global disease activity #acr24 @RheumNow https://t.co/u1XfqrQU1H

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#1165 📊 PBMCs of IIM patients with myocarditis(n=4) showed distinct gene expression v controls(n=4) v IIM alone(n=4)👇 💥 B-cell dysregulation may drive myocarditis in IIM 🎯Key immunological insights into🫀involvement in IIM #ACR24 @RheumNow @JuliePaikMD @jhrheumatology https://t.co/PceZUS929S

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#0322🔬 Myocarditis in Myositis(IIM) 📊 26% new IIM pt had myocarditis (ESC,Lake Louise) 💥 Anti-Ku most common MSA 💥Myocarditis a/w ⬆️heart failure, arrhythmia (43 v 6%;p=0.02) 🎯 Myocarditis🟰poor outcomes 🎯Cardiac MRI🟰earlier detection #ACR24 @RheumNow @JuliePaikMD https://t.co/yz0f2ozFVL

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#Baricitinib in refractory #myositis? A ‘weak’ trial design comparing #Bari to #Bari Rx started 12 weeks later in a small N =15 neat idea but NO answer 👇 looked like 👍 it worked BUT this is not the #RCT design that can show differences #ACR24 @RheumNow abst#1731 @ACRheum

Janet Pope Janetbirdope ( View Tweet)

Study of 168 patients with MDA5-positive Dermatomyositis finds that elevated IL-6 (≥ 13.41pg/m), lymphopenia (< 0.5 × 109) older age and high LDH predicted 6-month all-cause mortality in DM https://t.co/eHYrUtvsI9 https://t.co/SAy27Om2zu

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×